A mass balance study to investigate the metabolic disposition of a 400 mg single, oral dose of GSK189075 [remogliflozin etabonate] in healthy male subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2012
At a glance
- Drugs Remogliflozin etabonate (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 11 Aug 2007 New trial record.